Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: Roswell Park Cancer Institute
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
This description comes directly from the study's public registry record.
Christos Fountzilas, MD · 716-845-2300 · Christos.Fountzilas@roswellpark.org
Always discuss trial participation with your own doctor first.
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Good Samaritan University Hospital | West Islip, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06320717